Rapamycin extends lifespan in multiple animal models by inhibiting mTORTermmTORA cellular signaling hub that senses nutrients and growth signals and controls the balance between growth and maintenance.In glossary →, making it the most reproducible pharmacological longevity signal — and a live question for human healthspanTermHealthspanThe period of life spent with preserved function, resilience, and low disease burden.In glossary → trials.

Sources: [1][2]

Evidence standingEarly human
Key facts
Portal
Longevity Science
Stage
Preclinical robust, human trials early
Evidence
Early human
Reversible
Reversible
Reviewed
Jun 2026
Read time
7 min
Contents

Page status

Needs long-term functional-endpoint data in healthy adults

Key takeaways

  • Rapamycin is the most consistently lifespan-extending drug across model organisms, including mice started late in life.
  • The mechanism runs through mTORTermmTORA cellular signaling hub that senses nutrients and growth signals and controls the balance between growth and maintenance.In glossary →, a central controller of growth, metabolism, and autophagyTermAutophagyThe cell's recycling process that breaks down and reuses damaged components, important for stress resistance and maintenance.In glossary →.
  • Human evidence targets immune function and specific conditions; broad healthspanTermHealthspanThe period of life spent with preserved function, resilience, and low disease burden.In glossary → benefit is unproven.

Mechanism

mTORTermmTORA cellular signaling hub that senses nutrients and growth signals and controls the balance between growth and maintenance.In glossary → integrates signals about nutrients, energy, and growth factors. Sustained mTOR activity favors growth and protein synthesis; inhibiting it shifts cells toward maintenance, autophagyTermAutophagyThe cell's recycling process that breaks down and reuses damaged components, important for stress resistance and maintenance.In glossary →, and stress resistance — states associated with longer life in model organisms.

Rapamycin and related rapalogs inhibit mTORTermmTORA cellular signaling hub that senses nutrients and growth signals and controls the balance between growth and maintenance.In glossary → complex 1 strongly and complex 2 with chronic dosing. The dosing schedule matters: intermittent regimens aim to capture benefits while limiting immune suppression and metabolic side effects.

Human translation

The strongest human signal so far is immune: low-dose mTORTermmTORA cellular signaling hub that senses nutrients and growth signals and controls the balance between growth and maintenance.In glossary → inhibition improved vaccine response in older adults in trials of rapalogs. Interest has since widened to healthspanTermHealthspanThe period of life spent with preserved function, resilience, and low disease burden.In glossary → endpoints, and investigator-led trials have tested tolerability and biomarkers in generally healthy older people.

The open problem is endpoints. Aging is not an approved indication, side effects are real, and demonstrating benefit requires long, expensive trials with functional outcomes rather than biomarker shifts alone.

Open questions

  • Which intermittent dosing schedules separate benefit from immune suppression?
  • Do biomarker changes in humans predict functional healthspan gains?

Watchlist

Signals that would move this entry along the evidence scale.

Intermittent dosing trialsImmune aging endpointsRapalog selectivity

Key terms

References

  1. NIA Interventions Testing Program — rapamycin. National Institute on Aging
    Program that reproducibly extended mouse lifespan with rapamycin.
  2. mTOR inhibition and immune function in aging. Mannick et al., Science Translational Medicine, 2014
    Randomized trial showing improved vaccine response in older adults.

Cite this page

Future Human Atlas. “mTOR Inhibition and Rapamycin.” Last reviewed Jun 2026. https://future-human-wiki.vercel.app/articles/mtor-rapamycin

Suggest an edit